FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Psychometric analysis of the Neuro-QoL Fatigue in generalized Myasthenia Gravis (gMG) using data from a phase 3 trial. PMID 40515798 · Qual Life Res · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Repairing Myelin After Irradiated Pediatric Brain Tumor: A Magnetization Transfer Imaging Analysis. PMID 40515500 · Pediatr Blood Cancer · 2025-Sep Study is an oncology randomized Phase III trial with a drug intervention (metformin) but does not report a time-to-event efficacy endpoint as a primary or key secondary outcome. The primary outcomes are imaging (MTR) and cognitive measures, not survival or progression. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Co-Development, Evaluation, and Dissemination of a Lung Cancer Screening Digital Outreach Intervention: A Multiphase Randomized Clinical Trial. PMID 40505764 · J Am Coll Radiol · 2025-Sep The record describes a multiphase RCT of a digital outreach intervention to promote lung cancer screening. It is not a drug trial, lacks a Phase III/IIIb or Phase II/III drug intervention, and does not report a time-to-event efficacy endpoint for a drug. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial. PMID 40491042 · Cancer Commun (Lond) · 2025-Sep The record describes an open-label, randomized controlled trial in human HER2-negative breast cancer with primary and secondary time-to-event endpoints (DFS, OS, DDFS, DSS). It includes drug-containing interventions (TCX vs. TAC) and reports original results. The trial design and comparison to a standard adjuvant regimen are indicative of a definitive (Phase III/IIIb) trial, even if not explicitly stated in the provided metadata. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 4 Panel · risk visible |
| Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial. PMID 40483175 · Dig Liver Dis · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Home-based remote dance program with biopsychosocial model improves quality of life in breast cancer patients: A randomized controlled trial. PMID 40483151 · J Bodyw Mov Ther · 2025-Sep The study is a randomized controlled trial in human breast cancer patients, but it evaluates a non-drug intervention (a dance program) and uses quality of life as the primary endpoint, not a time-to-event efficacy endpoint. The trial phase is not explicitly stated as Phase III or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lidocaine for Neuropathic Cancer Pain (LiCPain): A Pilot Randomized Controlled Trial. PMID 40466924 · J Pain Symptom Manage · 2025-Sep The study is a randomized, double-blind, pilot/feasibility trial evaluating lidocaine for neuropathic cancer pain. While it is oncology-related, human, randomized, and includes a drug intervention, it is explicitly a pilot/feasibility study, not a definitive Phase III efficacy trial. The primary endpoints are feasibility metrics (completion rate) and pain intensity reduction, not a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. There is no mention of Kaplan-Meier analysis, hazard ratios, or any time-to-event analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Process of radical resection for advanced buccal cancer and the 'sandwich' technique for craniomaxillofacial defect repair using an anterolateral thigh chimeric myocutaneous flap. PMID 40461340 · J Craniomaxillofac Surg · 2025-Sep The study is a randomized oncology trial with a time-to-event endpoint (5-year OS) but is excluded because it does not involve a drug intervention (it is a surgical technique study) and does not specify a definitive Phase III trial phase. The phase is unclear and not explicitly established as Phase III/IIIb or II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis. PMID 40456670 · Ann Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comments on "Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-Based Multicenter Cluster Randomized Clinical Trial". PMID 40389179 · Gastroenterology · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effects of Nichi BRITE β-glucans as an onco-nutrition adjuvant in patients undergoing subtotal stomach-preserving pancreaticoduodenectomy (SSPPD) for pancreatic, bile duct and duodenal malignancies: A clinical study. PMID 40383031 · Nutrition · 2025-Sep The study meets criteria for oncology, human, randomized, and time-to-event endpoint. However, it is excluded because the trial phase is not definitively established as Phase III/IIIb or Phase II/III, and the primary intervention is a dietary supplement (β-glucan) rather than a conventional drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2. PMID 40320117 · Fertil Steril · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. PMID 40318924 · Int J Gynecol Cancer · 2025-Sep This is a phase 1b/2 trial protocol without results, not a Phase III/IIIb or Phase II/III randomized trial. The primary endpoints are safety and objective response rate (ORR), not a primary/key secondary time-to-event efficacy endpoint like OS, PFS, DFS, etc. The trial is ongoing with results expected in 2026, so it is a protocol without results, not an original formal result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. PMID 40287313 · Nutr Metab Cardiovasc Dis · 2025-Sep The study is a randomized controlled trial of semaglutide in type 2 diabetes patients, evaluating liver fat change via CT. It is not an oncology study and does not report a time-to-event efficacy endpoint for a malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients? PMID 40221951 · Clin Transl Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Early Intra-articular Hyaluronic Acid Injection After Anterior Cruciate Ligament Reconstruction Provides Short-Term Pain Relief and Improves Early Postoperative Function With No Clinical Benefits at 6 and 12 Months: A Randomized Controlled Trial. PMID 39983793 · Arthroscopy · 2025-Sep The study is a Level I randomized controlled trial in orthopedic surgery (anterior cruciate ligament reconstruction) with a hyaluronic acid intervention. It is not oncology, does not study a malignant neoplasm, and the primary efficacy endpoints are clinical function scores (Lysholm, IKDC) and pain scores (VAS), not time-to-event outcomes (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimizing Reversal of Muscle Relaxation with Sugammadex to Accelerate Discharge Readiness in Operative Laryngoscopy: A Randomized Clinical Trial. PMID 36594162 · Ear Nose Throat J · 2025-Sep The study is a randomized, single-blind clinical trial in anesthesiology evaluating sugammadex for reversal of neuromuscular blockade, with discharge readiness as a key outcome. It is not an oncology study, and the primary endpoint (time to extubation) and secondary endpoints do not meet the required time-to-event efficacy criteria for malignant neoplasms. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers. PMID 41234598 · Transl Lung Cancer Res · 2025-Oct-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Take the reins: a study protocol of a randomized controlled trial testing the effects of time-restricted eating vs. nutrition control on cancer-related fatigue among survivors of hematological malignancies. PMID 41174725 · BMC Nutr · 2025-Oct-31 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Real-World Evidence: A Randomized, Controlled, Single-Blinded Trial Comparing Oral Sulfate Tablets Versus PEG Formulations for Bowel Preparation Before Colonoscopy. PMID 42425913 · J Clin Gastroenterol · 2025-Oct-30 The record describes a randomized, single-blinded non-inferiority trial of bowel preparation formulations (oral sulfate tablets vs. PEG) for colonoscopy in patients needing screening/surveillance for colorectal cancer. The study's primary endpoints are cleansing efficacy (scored by an FDA scale), tolerability, and adverse events. It does not have an oncology-specific Phase III/IIIb or Phase II/III design, a drug-containing intervention for treating a malignant neoplasm, or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO). PMID 41168707 · BMC Cancer · 2025-Oct-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| European Study of Prostate Cancer Screening - 23-Year Follow-up. PMID 41160819 · N Engl J Med · 2025-Oct-30 This is a randomized trial of prostate cancer screening with PSA testing, not a drug intervention. The primary endpoint is prostate cancer mortality (a time-to-event outcome), and it reports original long-term results. However, it is not a drug-containing trial, and the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Narrative and cognitive behavioral therapy improve psychosocial and oncologic outcomes after abdominoperineal resection: a randomized controlled trial. PMID 41160369 · J Cancer Surviv · 2025-Oct-29 Eligibility excluded due to lack of a drug-containing intervention and unclear trial phase (not confirmed as Phase III/IIIb or Phase II/III). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian Cancer. PMID 41295472 · Vaccines (Basel) · 2025-Oct-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Serum CA19-9 and CEA levels, serum CAT, GSH, oxidised glutathione levels, 8-dihidro-2'-deoksiguanosina and F2-isoprostanes levels in colorectal cancer patients and Lactobacillus: A randomised double-blind controlled trial. PMID 41281285 · J Med Biochem · 2025-Oct-28 The study is a randomized, placebo-controlled trial in oncology patients, but it does not meet key eligibility criteria: the trial phase is not explicitly identified as Phase III/IIIb or Phase II/III, the intervention is a dietary supplement (Lactobacillus) rather than a drug, and the endpoints are biomarkers of oxidative stress and signaling pathways, not time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial. PMID 41151963 · BMJ Open · 2025-Oct-28 While the record describes a phase 3 randomized trial in oncology with a drug intervention, the primary and reported outcomes are participant experience and satisfaction measures (quality-of-life domain), not a primary/key secondary time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the cohort's inclusion criteria. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. PMID 40590852 · Blood Adv · 2025-Oct-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evolving Resection Strategies for Non-Small Cell Lung Cancers: Translating Trial Evidence to Real-World Practice. PMID 41228230 · Cancers (Basel) · 2025-Oct-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Improving physiotherapists' ability to recognise the presence of a serious pathology with a digital educational training: a mixed methods feasibility study. PMID 41146172 · BMC Med Educ · 2025-Oct-27 The record describes a mixed-methods feasibility study of a digital educational training for physiotherapists to improve recognition of serious pathologies (including cancer). It is not a clinical trial of a cancer drug, does not have a time-to-event efficacy endpoint, and is not a Phase II/III or Phase III randomized controlled trial of a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Advancing Knowledge of Values-Clarification Processes During Complex Decision-Making Among Older Adults With Advanced Cancer: Protocol for a Pilot Randomized Trial Using Simulated Patient-Clinician Encounters. PMID 41144958 · JMIR Res Protoc · 2025-Oct-27 This is a protocol for a pilot randomized trial focusing on shared decision-making processes and quality-of-life considerations. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. PMID 41144077 · J Gastrointest Cancer · 2025-Oct-27 The record is a randomized, prospective, human oncology trial with time-to-event endpoints and drug intervention, but the abstract does not explicitly state the trial phase (e.g., Phase II or III). Metadata cannot confirm the required phase criterion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Electroacupuncture for chemotherapy-induced gastrointestinal symptoms in colorectal cancer: protocol for a multicenter, three-arm, randomized controlled trial. PMID 41144022 · Int J Colorectal Dis · 2025-Oct-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Synergistic Effects of Microencapsulated Polyphenols and Concurrent Training on Metabolic Health and Fitness in Overweight/Obese Adults with Prediabetes. PMID 41228432 · Nutrients · 2025-Oct-25 The study is a randomized, placebo-controlled trial in humans with a drug intervention (polyphenol supplement) and original primary results. However, it is not an oncology study (focused on prediabetes/metabolic health), does not specify a Phase III or definitive Phase II/III trial phase, and lacks any time-to-event efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the eligibility criteria for this oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Focal Therapy Using High-Intensity Focused Ultrasound for Low- and Intermediate-Risk Prostate Cancer: Results from a Prospective, Multicenter Feasibility Trial. PMID 41228223 · Cancers (Basel) · 2025-Oct-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Proof-of-concept for a randomized factorial design strategy to build a complex online support program for cancer survivors with psychiatric symptoms: the IN-FACT-0 feasibility trial. PMID 41136825 · J Cancer Surviv · 2025-Oct-25 Study is a randomized factorial feasibility trial of non-drug interventions (psychological and lifestyle) for cancer survivors. It is not a Phase III trial, does not involve a drug intervention, and does not assess a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Fuzheng Quxie Formula Against Postoperative Metastasis of Lung Cancer in Stage IIA-IIIA With Negative Driver Genes: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial. PMID 41135941 · JMIR Res Protoc · 2025-Oct-24 This is a protocol for a randomized trial, not an original formal-result report. The abstract explicitly states it is a protocol (publication type 'Clinical Trial Protocol') and that results are not yet published. The phase is not confirmed as Phase III or II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Image-based Re-evaluation of the JCOG0911 Study Focusing on Tumor Volume and Survival, Disease Progression Diagnosis, and Radiomic Prognostication for Newly Diagnosed Glioblastoma. PMID 39567017 · Magn Reson Med Sci · 2025-Oct-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Accuracy of Flexible Sigmoidoscopy and MRI in Restaging Rectal Cancer after Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. PMID 41126443 · Ann Surg · 2025-Oct-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Expanded Hemodialysis with the Theranova Dialyzer on the Platelet-to-Lymphocyte Ratio and Inflammatory Markers. PMID 41295836 · Toxins (Basel) · 2025-Oct-22 The study is a randomized controlled trial in hemodialysis patients, evaluating a dialyzer (a device), not a drug. The primary endpoints are inflammatory biomarkers (PLR, TNF-α), not time-to-event efficacy outcomes. It is not an oncology study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ultrasound-guided erector spinae plane block versus rhomboid intercostal sub-serratus plane block for postoperative analgesia in open radical nephrectomy: a randomized clinical study. PMID 41120933 · BMC Anesthesiol · 2025-Oct-22 The study is a randomized trial in an oncology surgical context (open radical nephrectomy for renal malignancy) but it is an analgesia study comparing two nerve block techniques (ESPB vs. RISS) using bupivacaine. It is not a trial of a systemic drug intervention for cancer treatment (e.g., chemotherapy, targeted therapy, immunotherapy). The primary endpoint is morphine consumption (an analgesic outcome), not a time-to-event oncology efficacy endpoint like OS or PFS. Therefore, it does not meet the criteria for inclusion in the KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using Radiomics Features of Voxel-Wise DCE-MRI Time-Intensity-Curve Profile Maps. PMID 41153841 · Biomedicines · 2025-Oct-21 The study is a retrospective diagnostic/radiomics analysis to predict axillary lymph node metastasis in breast cancer. It is not a randomized trial, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study. PMID 41121202 · BMC Med · 2025-Oct-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. PMID 41061701 · Cell Rep Med · 2025-Oct-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Adaptive Blood Purification for Septic Shock (EABPSS): protocol for a randomised, multicentre, parallel controlled study. PMID 41120165 · BMJ Open · 2025-Oct-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Pre-existing infiltration with T cells and CD14+ myeloid cells is associated with treatment response to imiquimod in primary and recurrent vulvar high-grade squamous intraepithelial lesions. PMID 41120128 · J Immunother Cancer · 2025-Oct-20 The record describes a biomarker-focused secondary analysis of a phase III randomized trial. While it meets criteria for oncology, human, randomized, phase III, and drug intervention, it lacks a time-to-event efficacy endpoint (like OS, PFS, DFS, or their associated Kaplan-Meier/HR analysis). The primary outcome is a categorical clinical response. Therefore, it is excluded. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transfusion thresholds and other strategies for guiding red blood cell transfusion. PMID 41114449 · Cochrane Database Syst Rev · 2025-Oct-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting. PMID 40789109 · J Clin Oncol · 2025-Oct-20 The record describes a Phase III randomized trial with a drug intervention and primary time-to-event efficacy endpoint, meeting all eligibility criteria. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Community-Engaged Approach to Increase Physical Activity Among Black Individuals With Colorectal Cancer: Protocol for a Feasibility Randomized Controlled Trial of the Physical Activity Centers Empowerment Study. PMID 41105939 · JMIR Res Protoc · 2025-Oct-17 This is a protocol for a feasibility randomized controlled trial of a behavioral (physical activity) intervention. It does not present efficacy results, lacks a time-to-event primary endpoint, and has no drug intervention. It is not a Phase III/IIIb or Phase II/III report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Impact of personlized exercise prescription on muscle mass, physical function, and quality of life in postoperative pancreatic cancer patients undergoing da Vinci robotic surgery: a randomized controlled trial protocol. PMID 41102825 · Trials · 2025-Oct-16 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effectiveness, cost-effectiveness, and return on investment of the web-based MiLES intervention targeted at employers, to enhance successful return to work of employees with cancer: design of a randomized controlled trial. PMID 41102780 · Trials · 2025-Oct-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |